These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36702052)

  • 1. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.
    Ren P; Yu C; Zhang R; Nie T; Hu Q; Li H; Zhang X; Zhang X; Li S; Liu L; Dai W; Li J; Xu Y; Su H; Zhang L; Liu H; Bai F
    Eur J Med Chem; 2023 Mar; 249():115129. PubMed ID: 36702052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
    Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
    Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
    Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
    Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease.
    Chaibi FZ; Brier L; Carré P; Landry V; Desmarets L; Tarricone A; Cantrelle FX; Moschidi D; Herledan A; Biela A; Bourgeois F; Ribes C; Ikherbane S; Malessan M; Dubuisson J; Belouzard S; Hanoulle X; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2024 Oct; 276():116707. PubMed ID: 39068863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly potent covalent SARS-CoV-2 3CL
    Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
    Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
    Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network.
    Gu Z; Yan Y; Liu H; Wu D; Yao H; Lin K; Li X
    J Chem Inf Model; 2024 Apr; 64(8):3047-3058. PubMed ID: 38520328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of isatin derivatives as effective SARS-CoV-2 3CL protease inhibitors.
    Bao HL; Tu G; Yue Q; Liu P; Zheng HL; Yao XJ
    Chem Biol Drug Des; 2023 Oct; 102(4):857-869. PubMed ID: 37563791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease.
    Eberle RJ; Sevenich M; Gering I; Scharbert L; Strodel B; Lakomek NA; Santur K; Mohrlüder J; Coronado MA; Willbold D
    ACS Chem Biol; 2023 Feb; 18(2):315-330. PubMed ID: 36647580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
    Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
    Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.